Active polypeptide capable of promoting osteogenesis and inhibiting osteoclast and application of active polypeptide

A technology for inhibiting osteoclasts and active polypeptides, applied in the field of bone biomaterials and tissue engineering, can solve the problems of affecting selectivity and activity strength, not prominent conformation, and promoting fracture healing, so as to reduce osteoclasts and osteoporosis. , avoid risks and side effects, and facilitate the effect of large-scale production

Active Publication Date: 2018-07-13
WUHAN UNIV
View PDF7 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Teriparatide is currently the only bone formation-promoting drug approved by the US FDA. It can not only increase bone mass, inhibit bone resorption and reverse osteoporosis, but also may promote fracture healing. It is considered to be effective in the treatment of severe osteoporosis." "Breakthrough" progress, but the problem is that it is expensive, can only be administered by injection, can cause hypercalcemia, and even the risk of osteosarcoma, and cannot be used for a long time (2 years)
[0005] The biological activity of recombinant human parathyroid hormone (rhPTH 1-34) teriparatide is not stable enough, the main reason is that the polypeptide sequence is long (34 amino acids) and has a certain degree of flexibility, which may Curl occurs, and the spatial structure is still not stable, so the dominant conformation for binding to the receptor is not prominent, which affects the selectivity and activity intensity of binding to the receptor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Active polypeptide capable of promoting osteogenesis and inhibiting osteoclast and application of active polypeptide
  • Active polypeptide capable of promoting osteogenesis and inhibiting osteoclast and application of active polypeptide
  • Active polypeptide capable of promoting osteogenesis and inhibiting osteoclast and application of active polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] [Example 1] Synthesis of polypeptides PTHrP-1 and PTHrP-2

[0048] The polypeptide molecules required in the experiment were synthesized by an automatic peptide synthesizer, purified by high-performance liquid chromatography, and their purity and sequence were detected by mass spectrometry, amino acid and peptide analyzers. The sequences of PTHrP-1 and PTHrP-2 are respectively and The purity obtained by synthesis is greater than 95%, the molecular weight is 4543.07Da, and the molecular weight of PTHrP-2 is 4585.15Da. HPLC and MS such as figure 1 , figure 2 shown.

Embodiment 2

[0049] [Example 2] Toxicity test of polypeptide PTHrP-1

[0050] 1. Local skin irritation test

[0051] Take 3 healthy New Zealand white rabbits, male or female, weighing 2.0-2.5kg, cut off the rabbit hair on the back, observe for 2 days, no scars and irritation on the skin, inject 0.2ml of PTHrP-1 polypeptide solution with a concentration of 100ng / ml and normal saline respectively Subcutaneously on both sides of the spine, 10 points were taken on each side, and the injection site was observed at three time points of 1d, 3d, and 7d after injection. Observation at the three time points of 1d, 3d, and 7d showed no redness, swelling, or erythema at the injection site of the PTHrP-1 polypeptide solution and normal saline, suggesting that the PTHrP-1 polypeptide was not irritating to the animal body.

[0052] 2. Acute toxicity test

[0053] Choose 10 healthy mice, weighing 20-25g, half male and half male, and raise them in separate cages. Each mouse was intraperitoneally injecte...

Embodiment 3

[0056] [Example 3] Optimal concentration of polypeptide PTHrP-1 to promote osteogenic differentiation of MC3T3-E1 cells

[0057] Four kinds of PTHrP-1 polypeptide medium containing different concentrations (0ng / ml, 50ng / ml, 100ng / ml, 200ng / ml) were added to 24-well culture plate, each with 5 wells. Take the 3rd generation mouse MC3T3-E1 cells, the density is 1×10 5 / ml, add 0.5ml cell suspension to each well, at 37℃, the volume fraction is 5% CO 2 Cultured in an incubator, the medium was replaced every 2 days. After culturing for 14 days, ALP staining was performed using the ALP kit. It was found that in the culture wells of the three groups containing PTHrP-1 polypeptide, MC3T3-E1 cells aggregated and grew in layers, the cell shape gradually changed from round or round to polygonal or cubic, the secretion of extracellular matrix increased significantly, ALP Staining shows that reddish-brown granules or tan or coffee-colored granules appear in the cytoplasm of the cells, wh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
thicknessaaaaaaaaaa
lengthaaaaaaaaaa
Login to view more

Abstract

The invention discloses an active polypeptide capable of promoting osteogenesis and inhibiting osteoclast and application of the active polypeptide. N-terminal serine is phosphorylated on the basis ofPTH1-34, and three repeated sequences of glutamic acid or aspartic acid are introduced at a C terminal; the sequence of the polypeptide is shown in SEQ ID NO:1 or SEQ ID NO:2, and the polypeptide hasosteoinductive activity similar to BMP2 and an osteoclast inhibiting effect similar to parathyroid hormones (PTH). Random coils of the polypeptide can be avoided by bonding the C-terminal repeated sequences of the polypeptide to the surface of a calcium phosphate material or a material with a calcium phosphate coating, no addition of organic reagents is needed, and therefore the activity of the polypeptide is protected effectively; furthermore, slow controlled release can be achieved through cleavage of peptide bonds, and long-term intermittent injection of the PTH1-34 can be avoided, so thatthe injection pain of patients is reduced, and effects of osteoblast promotion and osteoporosis inhibition are achieved; a conventional viewpoint that the PTH1-34 cannot be administered locally is changed.

Description

technical field [0001] The invention relates to the field of bone biomaterials and tissue engineering, in particular to an active polypeptide capable of promoting osteogenesis and inhibiting osteoclastosis and its application. Background technique [0002] According to available data, about 200 million people in the world suffer from osteoporosis, and its incidence rate has risen to the seventh among chronic diseases. In my country, the number of osteoporosis patients over 60 years old has exceeded 80 million, and the incidence of osteoporotic fractures in the elderly has also reached 6.3%-24.4%. Osteoporotic fractures heal slowly, and the risk of complications during the healing process is high. At the same time, osteoporotic fractures have high disability and mortality rates, which seriously affect the quality of life of patients and increase the burden on the health system. The World Health Organization (WHO) has listed osteoporosis as one of the three major diseases aff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/635A61K38/29A61P19/08A61P19/10A61L27/54A61L27/10A61L27/20A61L27/12A61L27/36
CPCA61K38/00A61L27/10A61L27/12A61L27/20A61L27/3608A61L27/365A61L27/54A61L2300/252A61L2430/02C07K14/635
Inventor 李景峰王京京
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products